Roflumilast: The new orally active, selective phophodiesterase-4 inhibitor, for the treatment of COPD

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 1, 2014, Pages 85-96

  Tashkin, Donald P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chronic obstructive pulmonary disease; Exacerbations; Phosphodiesterase 4 inhibitor; Roflumilast

Indexed keywords

PLACEBO; ROFLUMILAST;

ANXIETY DISORDER; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PHARMACOLOGY; COMPARATIVE STUDY; DECREASED APPETITE; DEPRESSION; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HEART ATRIUM FIBRILLATION; HUMAN; NAUSEA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE DRUG DOSE; SUICIDAL BEHAVIOR; SUICIDE ATTEMPT; TREATMENT DURATION; WEIGHT REDUCTION;

AMINOPYRIDINES; ANIMALS; BENZAMIDES; CYCLOPROPANES; HUMANS; PHOSPHODIESTERASE 4 INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84890686350     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.837159     Document Type: Article

References (58)

1. Global initiative for chronic Obstructive Lung Disease: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Revised 2013. Available from: Http://www.goldcopd. org/uploads/users/ files/ GOLD-Report-2013Feb13.pdf
2. Gan WQ, Man SF, Senthilseilvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: A systematic review and a meta-analysis. Thorax 2004;59:574-80
3. Miller J, Edwards LD, Agusti A, et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med 2013;107:1376-84
4. Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes. The Future of COPD. Am J Respir Crit Care Med 2010;182:598-604
5. Vestbo J, Anderson W, Coxson H, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J 2008;31:869-73
6. Regan EA, Hokanson JE, Murphy JR, et al. Genetic epidemiology of COPD (COPDGene) study design. COPD 2010;7:32-43
7. The SPIROMICS Investigators. Design of the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS). Thorax 2013; In Press
8. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000;117(5 Suppl):398S-401S9
9. Anzueto A, Sethi S, Martinez F. Exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007;4:554-64
10. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363:1128-38
11. Gompertz S, O'Brien C, Baylery DL, et al. Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. Eur Respir J 2001;17:1112-19
12. Wedzicha JA, Seemungal TA, MacCallum PK, et al. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost 2000;84:210-15
13. Donaldson GC, Seemungal TAR, Bhowmik A, et al. Relationship between exacerbations frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847-52
14. Spencer S, Jones PW. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax 2003;58:589-93
15. Gunen H, Hacievliyagil SS, Kosar F, et al. Factors affecting survival of hospitalized patients with COPD. Eur Respir J 2005;26:234-41
16. Garcia-Aymerich J, Pons IS, Mannino DM, et al. Lung function impairment, COPD hospitalizations and subsequent mortality. Thorax 2011;66:585-90
17. Perera PN, Armstrong EP, Sherrill DL, et al. Acute exacerbations of COPD in the United States: Inpatient burden and predictors of costs and mortality. COPD 2012;9:131-41
18. Tashkin DP, Ferguson G. Combination bronchodilator therapy in the management of COPD. Respir Res 2013;14:49
19. Boswell-Smith V, Spina D. PDE4 inhibitors as potential therapeutic agents in the treatment of COPD - focus on roflumilast. Int J COPD 2007;2:121-9
20. Hatzelmann A, Schudt C. Anti-inflammatory and immunomodulary potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 2001;197:267-79
21. Martorana PA, Lunghi B, Lucattelli M, et al. Effect of roflumilast on inflammatory cells in the lungs of cigarette smoke-exposed mice. BMC Pulm Med 2008;8:17
22. Martorana PA, Beume R, Lucattelli M, et al. Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke. Am J Respir Crit Care Med 2005;172:848-53
23. Milara J, Armengot M, Banuls P, et al. Roflumilast N-oxide, a PDE4 inhibitor, improves cilia motility and ciliated human bronchial cells compromised by cigarette smoke in vitro. Br J Pharmacol 2012;166:2243-62
24. Rall TW. The xanthines. In: Gilman AG, Goodman LS, Gilman A, editors. The pharmacologic basis of therapeutics. Macmillan; New York: 1980. p. 592-607
25. Bergstrand H. Phosphodiesterase inhibition and theophylline. Eur J Respir Dis 1980;61:37-44
26. Wouters EFM, Bredenbroker D, Teichmann P, et al. Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-nai?ve, newly diagnosed type 2 diabetes mellitus. J Clin Endorinol Metab 2012;97:E1720-5
27. Grootendorst DC, Gauw SA, Verhoosel RM, et al. Reduction in sputum neurtophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 2007;62:1081-7
28. Hohlfeld JM, Schoenfeld K, Lavae-Mokhtari M, et al. Roflumilast attenuates pulmonary inflammation upon segmental endotoxin challenge in healthy subjects: A randomized placebo-controlled trial. Pulm Pharmacol Ther 2008;21:616-23
29. Rabe KF, O'Donnel D, Witte S, et al. Roflumilast - an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: A randomized controlled trial. Lancet 2005;366:563-71
30. Calverley PM, Sanchez-Toril F, McIvor A, et al. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;176:154-61
31. Rennard SI, Calverley PMA, Goehring UM, et al. Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD. Respir Res 2011;12:18 very severe COPD and symptoms of chronic bronchitis
32. Calverley PMA, Rabe KF, Goehring U-M, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: Two randomized clinical trials. Lancet 2009;374:685-94
33. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: From lung function to biomarkers. Eur Respir J 2008;31:418-68
34. Mahler DA, Witek TJ Jr. The MCID of the transition dyspnea index is a total score of one unit. COPD 2005;2:99-103
35. Fabbri LM, Calverely PMA, Izquierdo-Alonso JL, et al. Roflumilast in moderat-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: Two randomized clinical trials. Lancet 2009;374:695-703
36. Wedzicha JA, Rabe K, Martinez FJ, et al. Efficacy of roflumilast in the COPD frequent exacerbator phenotype. Chest 2013;143:1302-11
37. Oba Y, Lone NA. Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis. Ther Adv Respir Dis 2013;7:13-24
38. Yan JH, Gu WJ, Pan L. Efficacy and safety of roflumilast in patients with stable chronic obstructive pulmonary disease: A meta-analysis. Pulm Pharmacol Ther 2013; [Epub ahead of print]
39. FDA Advisory Committee Briefing Document. Daxas- (roflumilast) in Chronic Obstructive Pulmonary Disease. NDA 22-522. Available from: Www.fda. gov/AdvisoryCommittees/ CommitteesMeeting [Last accessed 7 April 2010]
40. Center for Drug Evaluation and Research. Application number 0225220 (ri9g1s000: Medical review(s). Available from: Http://www.accessdata.fda.gov/ drugsatfda-docs/nda/2011/ 022522Orig1s000MedR.pdf [Last accessed 21 November 2011]
41. Eschenhagen T. PDE4 in the human heart - major player or little helper? Br J Phamacol 2013;169:524-7
42. White WB, Cooke GE, Kowey PR, et al. Cardiovascular safety in patients receiving roflumilast for the treatment of chronic obstructive pulmonary disease. Chest 2013; [Epub ahead of print]
43. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004;350:1005-12
44. Samyshkin Y, Kotachie RW, Mork A-C, et al. Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdon. Eur J Health Econ 2013; [Epub ahead of print]
45. Samyshkin Y, Schlunegger M, Haefliger S, et al. Cost-effectivenss of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland. Int J COPD 2013;8:79-87
46. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89
47. Ferguson GT, Anzueto A, Fei R, et al. Effect of fluticasone proprionate/ salmeterol (250/50 mcg) or salmeterol (50 mcg) on COPD exacerbations. Respir Med 2008;102:1099-108
48. Baker WL, Baker EL, Coleman CI. Pharmacologic treatments for chronic obstructive pulmonary disease: A mixed-treatment comparison meta-analysis. Pharmacotherapy 2009;29:891-905
49. Wedzicha JA, Calverley PMA, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177:19-26
50. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543-54
51. Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily anticholinergic bronchodilator. Ann Intern Med 2006;143:317-26
52. Calverley PMA, Martinez FJ, Fabbri LM, et al. Does roflumilast decrease exacerbatins in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol. Int J COPD 2012;7:375-82
53. Ernst P, Gonzalez AV, Brassard P, et al. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007;176:162-6
54. Drummond MB, Dasenbrook EC, Pitz MW, et al. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: A systematic review and meta-analysis. JAMA 2008;300:2407-16
55. Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med 2011;105:930-8
56. Barrons R, Pegram A, Borries A. Inhaler device selection: Special considerations in elderly patients with chronic obstructive pulmonary disease. Am J Health Syst Pharm 2011;68:1221-32
57. Makela MJ, Backer V, Hedegaard M, et al. Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD. Respir Med 2013; [Epub ahead of print]
58. Gross NJ. Novel anti-inflammatory therapies for COPD. Chest 2012;142:1300-7